Find Academic Supervisors

Hai-Quan MaoView profile

Professor

• Biomaterials
• Regenerative Engineering
• Therapeutic Delivery
• +3 more

Hai-Quan Mao is a Professor of Materials Science and Engineering at Johns Hopkins University, with a joint appointment in the Biomedical Engineering Department (School of Medicine). He directs the Institute for NanoBioTechnology (INBT) and leads the Translational Tissue Engineering Center. His research focuses on biomaterials, regenerative engineering, and immunoengineering, particularly developing nanomaterials for therapeutic delivery and tissue regeneration. Mao holds 35 U.S. patents, co-founded two biotech companies, and received prestigious awards including National Academy of Inventors Fellow and NSF CAREER Award. Education: BS in Chemistry (1988) and PhD in Polymer Chemistry (1993) from Wuhan University. Postdoctoral training at Johns Hopkins (1995–1998), followed by roles at Johns Hopkins Singapore (1999–2003) before joining the Whiting School faculty. Research emphasizes nanofiber scaffolds for liver/nerve regeneration, DNA/lipid nanoparticle engineering for gene therapy, and artificial lymph node matrices for immunotherapy. His lab translates biomaterials innovations into clinical applications, with NIH-funded projects addressing cancer, malaria, and tissue damage. Awards include over 60 provisional patents, multiple Johns Hopkins translational awards, and Thalheimer Awards for research. He serves as associate editor of Biomaterials and editorial board member of major journals. Lab activities include scalable nanoparticle manufacturing, machine learning for material design, and collaborations with industry/clinical partners. Recent work includes lipid nanoparticle optimization for mRNA vaccines and exosome-based therapies for Crohn’s disease.

• Drug Delivery
• Nanomedicine
• Biopharmaceutics
• +7 more

Dr. Shyh-Dar Li is a Professor and Tong Louie Chair in Pharmaceutical Sciences at the University of British Columbia's Faculty of Pharmaceutical Sciences, where he also serves as Chair of Nanomedicine and Chemical Biology. With a BSc in pharmacy from National Taiwan University (1998) and PhD in pharmaceutical sciences from UNC Chapel Hill (2008), followed by postdoctoral training at UC San Diego's Moores Cancer Center (2009), Dr. Li has established himself as a leading researcher in advanced drug delivery systems. His research focuses on developing innovative nanomedicine platforms for targeted delivery of biological therapeutics including peptides, proteins, antibodies, and nucleic acids. Dr. Li's laboratory has pioneered several novel drug delivery approaches, particularly in lipid-based nanoparticles, phospholipid-free vesicles, and polymer systems for cancer immunotherapy, pain management, and protein delivery. His work bridges fundamental nanotechnology with translational applications for difficult-to-treat diseases. Analysis of his recent publications reveals a strong emphasis on tumor microenvironment modulation, endosomal escape mechanisms for nucleic acid delivery, and non-invasive delivery routes for protein therapeutics. His research demonstrates increasing sophistication in nanocarrier engineering, with recent work incorporating machine learning approaches to optimize nanoparticle design and expanding into immunomodulatory therapies that harness the body's immune system to fight cancer. Scientific Recognition: 2014 AFPC New Investigator Award 2013 AAPS New Investigator Award in Pharmaceutics and Pharmaceutical Technologies 2013 CIHR New Investigator Award 2013 CSPS Early Career Award 2012 Prostate Cancer Foundation Young Investigator Award Dr. Li's research program has been consistently supported by major Canadian funding agencies including CIHR, NSERC, and MITACS. He actively collaborates across disciplines and accepts graduate students into his research program, focusing on cutting-edge approaches to overcome biological barriers in drug delivery. His laboratory, the Laboratory of Targeted Drug Delivery and Nanomedicine, serves as a hub for innovation in pharmaceutical nanotechnology.

Helmuth GehartView profile

Professor

• Stem Cell Biology
• Cancer Biology
• Regenerative Medicine
• +2 more

Prof. Dr. Helmuth Gehart is a faculty member at the Institute of Molecular Health Sciences , ETH Zurich . He leads the Tumor and Stem Cell Dynamics research group, focusing on dynamic cell identity in regeneration and cancer. Research Interests : Stem cell-environment interactions, organoid technology, single-cell sequencing, and mechanisms of tissue repair/tumorigenesis. Publications : 10+ articles (2015-2024) on organoid models, stem cell dynamics, and cancer biology.

Jacques ArchambaultView profile

Professor

• Human Papillomavirus (HPV)
• Polyomavirus
• Viral DNA Replication
• +4 more

Dr. Jacques Archambault is a Professor in the Department of Microbiology and Immunology at McGill University , and an associate member of the Division of Experimental Medicine since 2016. His research focuses on the molecular biology and pathogenesis of human papillomaviruses (HPVs) and polyomaviruses (HPyVs), with an emphasis on their replication mechanisms as episomes in host cells. The Archambault laboratory employs functional genomics, proteomics, and chemical biology approaches to identify cellular pathways exploited by these viruses and develop high-throughput assays for screening small molecule inhibitors of viral replication. Analysis of his recent publications reveals a strong focus on HPV and HPyV replication machinery, including studies on the E1 helicase, UAF1-USP1 interactions, and structural characterization of viral proteins involved in DNA replication. His work bridges virology, oncology, and drug discovery, particularly targeting oncogenic HPV types implicated in anogenital and oropharyngeal cancers, as well as HPyVs like BKPyV and JCPyV that cause pathologies in immunosuppressed patients. Current efforts in the lab aim to elucidate the molecular mechanisms by which HPVs and HPyVs replicate their genomes and to develop antiviral therapies targeting these processes. Techniques such as fluorescence anisotropy, NMR spectroscopy, and crystallography are frequently employed to study protein-DNA and protein-protein interactions critical to viral replication.

Nika DanialView profile

Associate Professor

• Metabolic Biology
• Cancer Research
• Diabetes
• +4 more

Dr. Nika Danial is an Associate Professor of Cell Biology at Harvard Medical School and the Department of Cancer Biology at Dana-Farber Cancer Institute. She leads the Danial Lab, investigating metabolic mechanisms that regulate cellular adaptation to stress, with a focus on fuel utilization in health and disease. Dr. Danial holds additional roles as Co-Director of the NCI-funded T32 Training Program in Cancer Chemical Biology and Metabolism. Her research integrates biochemistry, mouse models, and metabolomics to study metabolic contributions to cancer, diabetes, and neurological disorders. Education: PhD from Columbia University (1999), postdoctoral training at Harvard Medical School and Dana-Farber under Dr. Stanley Korsmeyer. Key research areas include mitochondrial dynamics, glucose metabolism pathways, and the interplay between inflammation and metabolic signaling. The lab has pioneered studies on how metabolic flexibility impacts disease progression in pancreatic islets, lymphoma subtypes, and neuronal excitability. Publications highlight discoveries in mitochondrial fatty acid oxidation regulation, urea cycle anti-inflammatory mechanisms, and metabolic signatures in cancer subtypes. Her work has implications for developing therapies targeting metabolic vulnerabilities in diseases like diffuse large B-cell lymphoma and type 1 diabetes. The Danial Lab emphasizes rigorous training for the next generation of scientists through mentorship programs and interdisciplinary collaboration.

• Environmental Toxicology
• Reproductive Health
• Metabolic Disorders
• +3 more

Dr. Alison Holloway is a Professor at McMaster University's Faculty of Health Sciences, specializing in environmental toxicology and reproductive health. Her research focuses on the effects of environmental contaminants (e.g., oil sands pollutants, pesticides, endocrine disruptors) on maternal and child health, metabolic disorders, and developmental outcomes. She has conducted studies on naphthenic acids, synthetic food additives, and maternal exposure to pharmaceuticals like fluoxetine. Key research areas include: Environmental contaminants' impact on reproductive systems and placental function Metabolic disturbances caused by chemical exposures during critical developmental windows Neurobehavioral and gastrointestinal effects of prenatal drug exposure Assessment of urban air pollution on in vitro fertilization (IVF) success rates Her recent work highlights the role of the tryptophan-kynurenine pathway as a biomarker of environmental stress and the obesogenic effects of bisphenol analogs and food additives. Collaborations involve interdisciplinary teams addressing environmental health, with studies published in high-impact toxicology and public health journals. Dr. Holloway's research has informed policies on chemical safety and maternal health, emphasizing cross-species markers for organismal health and risk assessment of emerging contaminants like cannabis derivatives.

• Immunology
• Lipid Metabolism
• Infectious Diseases
• +3 more

Dijin Xu is an Associate Research Scientist in the Department of Microbial Pathogenesis at Yale School of Medicine, Yale University. His research focuses on lipid metabolism, immunology, and molecular mechanisms underlying metabolic disorders and host-pathogen interactions. He holds a PhD from Tsinghua University (2016). Education: PhD in Microbiology, Tsinghua University, 2016 Research Interests: Dr. Xu’s work spans immunology (e.g., B cell biology and somatic hypermutation), lipid metabolism (lipid droplet dynamics and adipose tissue homeostasis), and virology (antiviral defense mechanisms against SARS-CoV-2). His studies integrate cellular biology, molecular genetics, and biochemical approaches to understand disease processes. Publications Overview: His recent work explores mechanisms of lipid droplet regulation, metabolic disorder prevention, and immune system function. Notable contributions include studies on Rab GTPases in lipid storage and ELOF1’s role in antibody diversification. Labs & Affiliations: He is affiliated with the West Campus Integrative Science & Technology Center at Yale University, focusing on interdisciplinary research in cellular and molecular biology.

• Virology
• Vaccine Development
• Hepatitis Viruses
• +5 more

Lars Frelin is an Associate Professor in Virology at Karolinska Institutet, where he also serves as Programme Director for the Study Programme in Biomedical Laboratory Science and the Master Programme in Diagnostic Cytology. He is the Facility Manager for ANA Futura and a member of the VIVAC (Vaccines and Immunotherapies against Viruses And Cancer) research group led by Matti Sällberg at the Department of Laboratory Medicine, Division of Clinical Microbiology. Dr. Frelin's academic background includes: PhD from Karolinska Institutet (2004) Docent (Associate Professor) in Virology, Karolinska Institutet (2013) His research focuses on vaccine development against infectious diseases, particularly hepatitis viruses. Working with the VIVAC research group, he investigates novel immunotherapeutic approaches to combat viral hepatitis B, C, and D. His work spans from basic virology to translational research, with an emphasis on understanding viral immune evasion strategies and developing therapeutic vaccines that can overcome immune tolerance in chronic infections. Dr. Frelin's scientific contributions span over two decades, with recent work focusing on universal coronavirus vaccines, novel prime-boost strategies for hepatitis viruses, and understanding the immune response to viral infections. His research demonstrates a consistent trajectory toward developing immunotherapies that target viral entry mechanisms and enhance host immune responses against persistent viral infections. Dr. Frelin has secured multiple research grants from the Swedish Research Council, including: "Pathogenesis and immune evasion strategies of hepatitis viruses: New transgenic mouse models and new therapies" (2020-2022) "Pathogenesis and immune evasion strategies of hepatitis viruses: New transgenic mouse models and new therapies" (2017-2019) "Understanding the hepatitis C virus nonstructural 5A protein: A new target for antiviral therapies" (2012-2014) As Programme Director, he oversees academic programs in Biomedical Laboratory Science and Diagnostic Cytology, shaping the education of future laboratory medicine professionals. His leadership extends to serving on the Infrastructure Committee at Karolinska Institutet (2016-2019, 2019-2022) and managing the ANA Futura facility since 2020. Dr. Frelin is an active member of the VIVAC research group, which focuses on developing vaccines and immunotherapies against viruses and cancer. The group employs various approaches including DNA vaccine technology, viral vector systems, and novel delivery methods to enhance immune responses against challenging viral targets.

Angela KashubaView profile

Professor

• HIV Pharmacology
• Antiretroviral Drug Distribution
• Clinical Pharmacology
• +4 more

Angela Kashuba, Ph.D., is the John A. and Margaret P. McNeill, Sr. Distinguished Professor and Chair of the Division of Pharmacotherapy and Experimental Therapeutics at the UNC Eshelman School of Pharmacy. She serves as Director of the Clinical Pharmacology and Analytical Chemistry Core at the UNC Center for AIDS Research. Her research focuses on optimizing HIV treatment, prevention, and cure strategies through clinical pharmacology and analytical chemistry, with an emphasis on antiretroviral drug distribution in tissues and adherence monitoring. Education: Bachelor of Science in Pharmacy, University of Toronto (Canada) General Practice Residency, Women’s College Hospital (Toronto) Critical Care Pharmacy Practice, Mount Sinai Hospital (Toronto) Pharm.D., State University of New York at Buffalo Postdoctoral Pharmacology Training, Bassett Healthcare Clinical Pharmacology Research Center Research Interests: HIV drug pharmacokinetics and tissue distribution Development of novel adherence monitoring techniques (e.g., mass spectrometry imaging of hair) Optimizing dosing strategies for HIV prevention and cure interventions Impact of sex, gender, and comorbidities on drug efficacy Long-acting drug delivery systems (e.g., implants, biodegradable formulations) Grants & Projects: NIH P30-AI50410: UNC Center for AIDS Research Core NIH R01AI111891: Multi-Species Mechanisms of Drug Bio-distribution in HIV Tissue Reservoirs NIH/NIAID UM1AI126619: Collaboratory of AIDS Researchers for Eradication (CARE) Industry partnerships (e.g., Chimerix, TaiMed Biologics) Awards: Rawls-Palmer Progress in Medicine Award (ASCPT, 2023) John A. and Margaret P. McNeill, Sr. Distinguished Professorship (UNC, 2013) Labs & Collaborations: Director of the Clinical Pharmacology & Analytical Chemistry Laboratory, pioneering mass spectrometry imaging and drug reservoir analysis. Future Work: Advancing ultra-long-acting HIV PrEP implants Exploring sex-specific pharmacology in transgender populations Global HIV prevention initiatives via data sharing (HIV Pharmacology Data Repository)

• Redox Biology
• Cancer Research
• Drug Metabolism
• +4 more

Zhiwei Ye is an Associate Professor in the Department of Pharmacology & Immunology at the College of Medicine, Medical University of South Carolina. His research focuses on redox biology, cancer mechanisms, and drug metabolism with a particular emphasis on mitochondrial function, oxidative stress, and therapeutic resistance. He holds a PhD in Pharmaceutical Science from Katholieke Universiteit Leuven (Belgium, 2009) and prior degrees from Zhejiang University (China). PhD in Pharmaceutical Science, 2009 – Katholieke Universiteit Leuven, Belgium Master in Pharmaceutical Science, 2005 – Katholieke Universiteit Leuven, Belgium Master in Medicine, 2003 – Zhejiang University, China B.S. in Pharmacy, 2000 – Zhejiang University, China Dr. Ye’s research explores how redox regulation impacts cancer progression, drug resistance, and metabolic disorders. His work integrates enzymology (e.g., GSTP, PDI), mitochondrial dynamics, and zebrafish models to study mechanisms like S-glutathionylation, VDAC targeting, and drug-transporter interactions. Recent studies highlight novel therapeutic strategies for hepatocellular carcinoma, melanoma, and myeloma through modulation of redox pathways. Publications emphasize translational research bridging basic biology and clinical applications, including drug development (e.g., Telintra) and understanding treatment resistance in malignancies. His work also addresses metabolic disease mechanisms, such as hepatic steatosis and drug-induced renal toxicity. No scientific awards explicitly mentioned in provided texts. Active in grant-funded research areas like cancer biology and redox signaling. Collaborates on projects involving drug-transporter profiling in hepatocytes and cellular stress responses.

• Cancer Drug Discovery
• Medicinal Chemistry
• Kinase Inhibitors
• +4 more

Dr. Celine Cano is a research-focused academic at Newcastle University's Faculty of Medical Sciences within the School of Pharmacy and Biomedical Sciences, with a distinguished career spanning nearly two decades in cancer drug discovery and medicinal chemistry. Her work centers on developing targeted therapies, particularly kinase inhibitors and MDM2-p53 interaction antagonists, with significant contributions to understanding molecular mechanisms in oncology. Her research interests encompass cancer drug discovery , medicinal chemistry , and kinase inhibitor development , with specialized expertise in covalent drug design, fragment-based screening, and structural optimization of anticancer agents. Dr. Cano has pioneered work on MDM2-p53 inhibitors, ERK5 modulators, and PROTAC technologies, focusing on enhancing therapeutic indices while minimizing toxicity through precise molecular engineering. Analysis of her 15 most recent publications (2020-2024) reveals a dominant focus on targeted cancer therapies , particularly small-molecule antagonists of protein-protein interactions (MDM2-p53) and kinase inhibitors (ERK5, Nek2, NIK). Her work demonstrates consistent innovation in covalent drug design , pharmacokinetic optimization , and structural biology approaches to overcome resistance mechanisms. Notable trends include the development of differentiated pharmacokinetic profiles in next-generation MDM2 antagonists and sophisticated linker strategies for PROTACs. Dr. Cano maintains extensive collaborative networks across Newcastle University's cancer research ecosystem, particularly with groups led by Professors Ian Hardcastle, Bernard Golding, and Steve Wedge. Her research has been instrumental in advancing multiple drug candidates through preclinical development, with several publications describing compounds that have progressed to therapeutic evaluation.

• Pediatric Critical Care Medicine
• Developmental Biology
• Organogenesis
• +7 more

Clifford W. Bogue, MD , is the Waldemar Von Zedtwitz Professor of Pediatrics, Chair of the Department of Pediatrics at Yale School of Medicine, and Chief of Pediatrics for the Yale New Haven Health System. He has been a faculty member at Yale since 1993 and has held numerous leadership roles, including Interim Chairman of Pediatrics, Chief Medical Officer of Yale-New Haven Children’s Hospital, and Director of Pediatric Critical Care programs. Education: BA and MD from the University of Virginia; Residency and Chief Residency at Vanderbilt University; Fellowship in Pediatric Critical Care at Yale. Dr. Bogue is a pediatric critical care specialist whose research centers on the molecular mechanisms of organ development, particularly the role of the Hhex gene in liver, cardiovascular, and lung organogenesis. His lab used mouse models to uncover critical genetic pathways in embryonic development, with implications for regenerative medicine. His recent work also extends into pediatric public health, critical care infrastructure, and health equity. An analysis of his recent publications reveals a sustained focus on developmental genetics, with increasing engagement in clinical and policy-oriented research in pediatrics. His work spans molecular biology, translational models, and national health initiatives, reflecting a broad scholarly impact. His scientific honors include: President of the American Pediatric Society (2024–2025) Norman J. Siegel Faculty Award Marna P. Borgstrom Lifetime Achievement Award Consistent recognition in Best Doctors in America since 2004 Honorary M.A. from Yale University Dr. Bogue has been deeply involved in training the next generation of physician-scientists, serving as PI of an NIH T32 program, Training Director of the Yale Child Health Research Center (K12), and mentor in the MD/PhD program. He has contributed to national pediatric research policy through roles in the American Academy of Pediatrics, NIH advisory committees, and the Charles H. Hood Foundation. He leads or has led significant research initiatives, including an NIH-funded program on cardiopulmonary development and the Bedside to Bench seminar for medical students. His leadership extends to national boards and editorial roles, including Section Editor for Current Opinion in Pediatrics .

Ype P. de JongView profile

Assistant Professor

• Viral Hepatitis
• Hepatology
• Liver Disease
• +7 more

Dr. Ype P. de Jong is an Assistant Professor of Medicine at Weill Cornell Medical College of Cornell University and an Attending Physician at New York-Presbyterian Hospital. He completed his medical and doctoral training at the University of Amsterdam, followed by internal medicine and gastroenterology fellowships at Mount Sinai Hospital, New York. His research focuses on hepatitis virus immune evasion, liver disease modeling, and gene therapy applications. Education M.D., University of Amsterdam Faculty of Medicine (2003) Ph.D., University of Amsterdam (2002) Research Interests Dr. de Jong investigates hepatitis virus persistence mechanisms, develops advanced liver disease models, and explores gene therapy applications for hemophilia and liver conditions. His work bridges clinical hepatology with translational research on viral immune evasion and hepatocyte engineering. Scientific Awards Cum Laude (PhD thesis), University of Amsterdam (2002) Hippocrates Prize (Best Medical Thesis in Netherlands), Leiden University (2003) Appointments Assistant Professor of Medicine, Weill Cornell Medical College Attending Physician, New York-Presbyterian Hospital Visiting Clinical Fellow, The Rockefeller University

Linda KockView profile

Assistant Professor

• Biomechanics
• Tissue Engineering
• Orthopaedics
• +4 more

Linda Kock is an Assistant Professor (Part-time) in the Department of Biomedical Engineering at Eindhoven University of Technology, specializing in the Orthopaedic Biomechanics research group. Her work focuses on developing ex vivo models for studying bone dynamics, liver function, and tissue engineering applications. Dr. Kock's research primarily centers on biomechanics and tissue engineering, with particular emphasis on: Ex vivo culture systems for bone and cartilage tissue Liver perfusion and transplantation models Organoid development and application in regenerative medicine Longitudinal monitoring of tissue dynamics using advanced imaging techniques Development of alternatives to animal experimentation in medical research Her recent publications demonstrate a strong focus on creating clinically relevant ex vivo models that bridge the gap between laboratory research and clinical applications, particularly in orthopaedics and liver transplantation. She has developed innovative approaches for monitoring bone remodeling through micro-CT scanning and has investigated the use of slaughterhouse-obtained livers as alternatives to laboratory pigs for perfusion research. Dr. Kock has received research funding from several prestigious sources including the European Union's Horizon 2020 research program under Marie Sklodowska-Curie grant agreements and the Netherlands Organization for Scientific Research through the ERC Proof of Concept program and Gravitation Program. She is actively contributing to the advancement of regenerative medicine techniques that align with the 3Rs principle (Replacement, Reduction, Refinement) in medical research, providing valuable platforms for testing drug treatments and evaluating implant performance under controlled conditions that better reflect human physiology.

• T cell immunology
• Immune tolerance
• Checkpoint inhibitor immunotherapy
• +5 more

Martina Damo serves as Assistant Professor in the Department of Medicine, Section of Rheumatology at the University of Chicago School of Medicine, where she joined the faculty in October 2023. She leads a research laboratory investigating immune checkpoint receptors on T cells and their role in immunological tolerance, with particular focus on how checkpoint blockade immunotherapy causes immune-related adverse events (irAEs) in cancer patients. Her work aims to identify druggable tolerance pathways and develop bioengineered therapies for tolerance modulation. Dr. Damo's educational background includes: PhD in Bioengineering from Swiss Federal Institute of Technology in Lausanne (EPFL), 2016 Postdoctoral Fellowship in Immunobiology at Yale University, 2022 Instructor position at Yale University, 2023 Her research centers on T cell immunology in physiological and pathological contexts, with emphasis on peripheral tissue immunity. She investigates mechanisms of immune tolerance in skin and liver environments, neoantigen recognition by T cells, and the pathogenesis of irAEs following cancer immunotherapy. Her laboratory employs advanced techniques including clonal lineage tracing, mouse models of cancer and autoimmunity, and bioengineering approaches for therapeutic development. Analysis of her publication history (2011-2025) reveals an evolving research trajectory from foundational work in antigen-specific tolerance and gene therapy (2011-2015) to contemporary focus on T cell exhaustion, checkpoint biology, and cancer immunotherapy applications (2018-2025). Her most cited works involve CD8+ T cell dynamics in tumors and viral infections, with consistent emphasis on translational applications. Key thematic areas include T cell tolerance mechanisms, irAE pathogenesis, and bioengineered tolerance-inducing therapeutics. Dr. Damo actively mentors within her research laboratory and collaborates extensively with immunology researchers including Jeffrey Hubbell, Thomas Gajewski, and Melody Swartz. Her work has attracted significant attention with multiple publications exceeding 100 citations, substantial social media engagement (over 250 X posts), and patent references (23 patents citing her work). She maintains active research funding supporting her laboratory's investigations into T cell tolerance pathways. Her laboratory operates within the University of Chicago's immunology research ecosystem, collaborating with colleagues in the Department of Medicine including Maria-Luisa Alegre and James Curran. Current projects focus on developing targeted approaches to prevent irAEs while preserving anti-tumor efficacy of checkpoint inhibitors, leveraging her expertise in tissue-specific immune regulation.